IUPAC name
5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-hexahydro-2H-cyclopenta[b]furan-2-ylidene]pentanoic acid
SMILES
[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])CC(O2)=CCCCC(O)=O
Compound class
Platelet Aggregation Inhibitors; Antihypertensive Agents; Antithrombotic Agents; Blood and Blood Forming Organs; Platelet Aggregation Inhibitors Excl. Heparin; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inducers;
Therapeutic area
For the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy.
Common name
Epoprostenol
IUPAC name
5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-hexahydro-2H-cyclopenta[b]furan-2-ylidene]pentanoic acid
SMILES
[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])CC(O2)=CCCCC(O)=O
INCHI
InChI=1S/C20H32O5/c1-2-3-4-7-14(21)10-11-16-17-12-15(8-5-6-9-20(23)24)25-19(17)13-18(16)22/h8,10-11,14,16-19,21-22H,2-7,9,12-13H2,1H3,(H,23,24)/b11-10+,15-8?/t14-,16+,17+,18+,19-/m0/s1
FORMULA
C20H32O5
Common name
Epoprostenol
IUPAC name
5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-hexahydro-2H-cyclopenta[b]furan-2-ylidene]pentanoic acid
Molecular weight
352.465
clogP
3.414
clogS
-2.210
HBond Acceptor
5
HBond Donor
3
Total Polar Surface Area
86.99
Number of Rings
2
Rotatable Bond
10
| Drug ID | Common name | Structure CAS | SMILE | Frequency |
|---|---|---|---|---|
| FDBF00004 | acetic acid |
|
CC(=O)O | 0.0687 |
| FDBF00041 | ethanol |
|
CCO | 0.1474 |
| FDBF00061 | butyric acid |
|
CCCC(=O)O | 0.0131 |
| FDBF00620 | (2S)-but-3-en-2-ol |
|
C=CC(O)C | 0.0031 |
| FDBF02803 | (2Z,3aR,4R,5R,6aS)-2-ethylidene-4-vinyl-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-5-ol |
|
C(=C)C1C2C(OC(=CC)C2)CC1O | 0.0003 |
| FDBF02805 | (3aR,4R,5R,6aS)-4-[(E)-3-hydroxyprop-1-enyl]-2-methylene-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-5-ol |
|
C(=CCO)C1C2C(OC(=C)C2)CC1O | 0.0003 |
| FDBF02807 | (2Z,3aR,4R,5R,6aS)-2-propylidene-4-vinyl-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-5-ol |
|
C(=C)C1C2C(OC(=CCC)C2)CC1O | 0.0003 |
| FDBF02809 | (2Z,3aR,4R,5R,6aS)-2-ethylidene-4-[(E,3S)-3-hydroxybut-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-5-ol |
|
C(=CC(O)C)C1C2C(OC(=CC)C2)CC1O | 0.0003 |
| FDBF02810 | (2Z,3aR,4R,5R,6aS)-4-[(E)-3-hydroxyprop-1-enyl]-2-propylidene-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-5-ol |
|
C(=CCO)C1C2C(OC(=CCC)C2)CC1O | 0.0003 |
| FDBF02812 | (2Z,3aR,4R,5R,6aS)-4-[(E,3S)-3-hydroxybut-1-enyl]-2-propylidene-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-5-ol |
|
C(=CC(O)C)C1C2C(OC(=CCC)C2)CC1O | 0.0003 |
